This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q2 performance will likely reflect Skyrizi and Rinvoq sales trying to make up for the declining Humira sales following the loss of U.S. exclusivity.
Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DHS
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $137.68, moving +0.81% from the previous trading session.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
The Zacks Analyst Blog Highlights Walmart, AbbVie, Nike, Uber and PayPal
by Zacks Equity Research
Walmart, AbbVie, Nike, Uber and PayPal are included in this Analyst Blog.
Top Analyst Reports for Walmart, AbbVie & Nike
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), AbbVie Inc. (ABBV) and Nike, Inc. (NKE).
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $133.59, marking a -1.03% move from the previous day.
Is WisdomTree U.S. High Dividend ETF (DHS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DHS
Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study
by Zacks Equity Research
Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.
Novo Nordisk (NVO) Falls on EMA Safety Review of Obesity Drugs
by Zacks Equity Research
Novo Nordisk's (NVO) important diabetes care and obesity drugs are under review by the EMA's safety committee for the risk of suicidal behavior with its use. The stock falls 3%.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Roche (RHHBY) Blood Cancer Drug Columvi Wins EC Approval
by Zacks Equity Research
Roche's (RHHBY) blood cancer portfolio gets a boost with the EC's approval of Columvi (glofitamab-gxbm) for treating patients with R/R DLBCL.
Bausch Health (BHC) Secures $600M Financing Facility, Stock Up
by Zacks Equity Research
Bausch (BHC) enters into a $600 million non-recourse financing facility with KKR to boost liquidity.
Novartis (NVS) Entresto Patent Faces Setback, Stock Down
by Zacks Equity Research
Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.
Zacks.com featured highlights include Dillard's, Suzano, Atkore, Nexstar Media Group and AbbVie
by Zacks Equity Research
Dillard's, Suzano, Atkore, Nexstar Media Group and AbbVie are part of the Zacks Screen of the Week article.
Buy 5 High ROE Stocks as Market Rally Skids on ADP Jobs Data
by Supriyo Bose
Dillard's (DDS), Suzano (SUZ), Atkore (ATKR), Nexstar (NXST) and AbbVie (ABBV) are some of the stocks with high ROE to profit from as markets decline on better-than-expected ADP jobs data.
AbbVie (ABBV) Stock Moves -0.27%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $137.25, moving -0.27% from the previous trading session.
Sarepta (SRPT) Sells Priority Review Voucher for $102M
by Zacks Equity Research
Sarepta (SRPT) sells its priority review voucher that was awarded following the FDA's approval to Elevidys gene therapy for treating DMD. The company will invest these proceeds into R&D.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results
by Zacks Equity Research
While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance in overall survival.
Novartis (NVS) to Divest Xiidra, SAF312 to Streamline Focus
by Zacks Equity Research
Novartis (NVS) signs a deal to divest Xiidra and SAF312 (libvatrep) to Bausch + Lomb for $2.5 billion.
BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy
by Zacks Equity Research
Following FDA's approval, BioMarin's (BMRN) Roctavian becomes the first gene therapy for treating severe hemophilia A.